Recently, a meta‐analysis of multiple phase III trials comprising 1656 patients with unresectable HCC demonstrated that anti‐PD1 or anti‐PD‐L1 treatments were less effective in NASH‐driven HCC compared with viral HCC5 (Figure 1C,D). Here, CD274 is linked to hepatocellular carcinoma.